用药基因学指导的阿片类药物治疗疼痛:随机对照试验的系统审查和元分析
S Jethwa1, M Ball2, K Langlands3
1University of Cambridge, Cambridge, UK. sj648@cantab.ac.uk.
The pharmacogenomics journal
|July 12, 2025
概括
药基因学指导的阿片类药物处方减少了阿片类药物的消费,但没有显著改变成年人的疼痛强度. 需要进一步的研究来确认药物基因组学是否可以改善阿片类药物治疗的结果.
科学领域:
- 药物基因组学 药物基因组学
- 临床药理学 临床药理学
- 基于证据的医学基于证据的医学.
背景情况:
- 优化阿片类药物治疗受到影响患者反应的遗传变异的阻碍.
- 个性化医疗方法,如药物遗传学指导的处方,显示出改善阿片类药物治疗的潜力.
- 药物基因学指导的阿片类药物处方的临床有效性需要严格的评估.
研究的目的:
- 系统地审查和元分析随机对照试验 (RCT),比较药物基因组指导与成年人标准阿片类药物处方.
- 评估药物基因组指导处方对阿片类药物消费,疼痛强度和不良事件的影响.
- 使用GRADE标准评估证据的确定性,使用RoB 2评估偏差风险.
主要方法:
- 系统性审查和RCT的元分析.
- 遵守PRISMA报告指南.
- 包括来自2496篇选文章的6个RCT.
- 对偏见风险和证据确定性的评估.
主要成果:
- 药基因组指导的处方与明显减少的阿片类药物消费有关 (SMD -0.38,p=0.01).
- 在药物基因组指导和标准处方组之间没有观察到疼痛强度的显著差异 (SMD -0.31,p=0.30).
- 一项试验表明,随着药基因组指导 (p<0.01),不良事件的统计显著减少.
结论:
- 药基因学指导的阿片类药物处方可能会减少阿片类药物消费.
- 目前的证据并不表明疼痛强度有显著改善.
- 需要进一步的研究,以确定药物基因组学在优化阿片类药物治疗结果和减少不良事件方面的临床实用性.
相关概念视频
Analgesia and Pain Management
3.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.4K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.6K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.6K
Dosage Regimen: Individualization
406
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
406
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129


